Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 4, 2003, Pages 206-213

  Shu, En ^a   Matsuno, Hiroyuki ^a   Ishisaki, Akira ^a   Kitajima, Yasuo ^a   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Fibrinolytic components; Pulmonary embolism; Thromboembolism; Venous thrombus

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMORAL VEIN; HISTOPATHOLOGY; JUGULAR VEIN; KNOCKOUT MOUSE; LUNG EMBOLISM; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; VEIN OCCLUSION; VEIN THROMBOSIS; WILD TYPE;

ACUTE DISEASE; ANIMALS; BLOOD COAGULATION; DRUG EVALUATION, PRECLINICAL; FACTOR XA; HEPARIN; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NAPHTHALENES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPIONIC ACIDS; PULMONARY EMBOLISM; SURVIVAL ANALYSIS; SURVIVAL RATE; VENOUS THROMBOSIS;

EID: 10844253740     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081510     Document Type: Article

References (27)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population-based perspective of the hospital incidence and casefatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
2. Sutton GC, Hall RJ, Kerr IH: Clinical course and late prognosis of treated subacute massive, acute minor, and chronic pulmonary thromboembolism. Br Heart J 1977;10:1135-1142.
3. Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Buller HR: Travel and risk of venous thrombosis. Lancet 2000;356:1492-1493.
4. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-3124.
5. Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P: Growth factor control of extracellular proteolysis. Cell Differ Dev 1990;32:313-318.
6. Kruger S, Haage P, Hoffmann R, Breuer C, Bucker A, Hanrath P, Gunther RW: Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography. Chest 2001;120:1556-1561.
7. Lang IM, Moser KM, Schleef RR: Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol 1998;18:808-815.
8. Gallus AS: Thrombolytic therapy for venous thrombosis and pulmonary embolism. Baillières Clin Haematol 1998;11:663-673.
9. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC: DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-1038.
10. Flores J, Garcia-Avello A, Flores VM, Navarro JL, Canseco F, Perez-Rodriguez E: Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism. Arch Pathol Lab Med 2003;127:310-315.
11. Bottiger C, Koch W, Lahn C, Mehilli J, von Beckerath N, Schomig A, Kastrati A: 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 2003;146:855-861.
12. Roller RE, Schnedl WJ, Korninger C: Predicting the risk of restenosis after angioplasty in patients with peripheral arterial disease. Clin Lab 2001;47:555-559.
13. Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, Travis WD, Martinez FJ, Murray S, Simon RH: A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003;9/1-2:52-56.
14. Senno SL, Pechet L: Clinical implications of elevated PAI-1 revisited: Multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: A case report and review of the literature. J Thromb Thrombolysis 1999;8/2:105-112.
15. Matsuno H, Kozawa O, Niwa M: Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999;81:601-604.
16. Hashimoto M, Onobayashi Y, Oiwa K, Giddings JC, Yamamoto J: Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo. Thromb Res 2002;106:165-168.
17. Nishida M, Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T: tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor. J Cardiovasc Pharmacol 2000;36:770-775.
18. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequence of loss of plasminogen activator gene function in mice. Nature 1994;368:419-424.
19. Matsuno H, Uematsu T, Nagashima S, Nakashima M: Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods 1991;25:303-317.
20. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T: Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thromb Haemost 2002;87/1:98-104.
21. Kawasaki T, Sato K, Sakai Y, Hirayama F, Koshio H, Taniuchi Y, Matsumoto Y: Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998;79:410-416.
22. Bdeir K, Murciano JC, Tomaszewski J, Koniaris L, Martinez J, Cines DB, Muzykantov VR, Higazi AA: Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood 2000;96:1820-1826.
23. Butte AN, Houng AK, Jang IK, Reed GL: Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Circulation 1997;95:1886-1891.
24. Robinson BR, Houng AK, Reed GL: Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000;102:1151-1157.
25. Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparinantithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989;86:3619-3623.
26. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
27. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR: Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995;92:962-967.